Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 154
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Completed
15 and over
Other
LAL-RI/96
NCT00494897
Last Modified:
3/14/2007
2.
Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
1 to 20
NCI
POG-8698
POG-8698
Last Modified:
4/12/2007
3.
Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
1 to 21
NCI
POG-8741/42
POG-8741, POG-8742, POG-8741/42
4.
Phase III Study with CACP vs ADR/CTX/CACP & Phase II Study with VM-26 for Disseminated Transitional Cell Urinary Tract Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
under 75
NCI
EST-1878
Last Modified:
7/1/1988
5.
Phase II/III Evaluation of IPP and VM-26 as Single Agents vs Combination Chemotherapy with CAV (CTX/ADR/VCR) in Patients with Extensive Small Cell Lung Cancer (Summary Last Modified 07/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
NCI
EST-1588
EST-1588
Last Modified:
7/1/1990
6.
Phase II/III Study of Teniposide with vs without Whole-Brain Radiotherapy in Patients with Small Cell Lung Cancer Metastatic to the Brain (Summary Last Modified 07/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
75 and under
EORTC-08891
Last Modified:
3/9/2007
7.
Phase III Randomized Study of "Iceberg" Radiotherapy vs No Further Treatment for Stage II/III/IV Intermediate- and High-Grade NHL in CR Following Chemotherapy with DOX/VM-26/CTX/PRED/VCR/BLEO or a Comparable Regimen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
50 and over
EORTC-20932
Last Modified:
5/7/2008
8.
Phase III Randomized Study of High Versus Standard Dose Methotrexate and High Dose Cytarabine and Asparaginase Rescue Versus Standard Dose Cytarabine and Teniposide During Intensive Continuation and Consolidation in Children with High Risk Acute Lymphocytic Leukemia: An ALinC #16 Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
1 to 21 at diagnosis
NCI
POG-9406
POG-ALINC-16/HR, POG-9406
9.
Phase III Comparison of IPP/AMSA/VP-16 vs IPP/AMSA/VM-26 in Patients with Relapsed Hodgkin's and non-Hodgkin's Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
NCI-D81-043-156
MDA-DT-8071
Last Modified:
2/2/2007
10.
Postoperative Radiotherapy and Combination Chemotherapy with BCNU, PCB, HU, and VM-26 for Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
over 15
BTSG-8001
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute